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INTRODUCTION
Peroxiredoxins (Prdxs) are a family of
antioxidant proteins that protects cells
from oxidative damage via reduction of
peroxides using thioredoxin (TXN) and,
in some cases glutaredoxin, as the elec-
tron donor and also functions as molecu-
lar chaperones and regulators of signal
transduction (1,2). A number of studies
have shown that Prdxs are secreted from
cancer or virus-infected cells (3), are
present in biological fluids such as bron-
chiolar lavage (4) and serum (5) as well
as on the membrane of lymphocytes
from rheumatoid arthritis patients (6).
Prdxs are also known as natural killer
enhancing factors (NKEF) due to early
observations that these proteins could
enhance natural killer cell cytotoxicity
against tumor cells (7). Soon after, the an-
tioxidant properties of both NKEF-A and
B (Prdx I and II respectively) were
demonstrated in erythrocytes (8). The as-
sociation of oxidative stress with inflam-
mation has been known for some time,
but the precise relationship and mecha-
nisms by which these two phenomena
are related are not well understood.
In a previous study using redox pro-
teomics, a technique originally devel-
oped to identify intracellular glu-
tathionylated proteins (9), we identified
Prdx2 among the proteins released from
mouse macrophages in response to LPS
under specific forms of cysteine oxida-
tion, including formation of disulfide-
linked homodimers and mixed disulfides
with glutathione (glutathionylation) (10).
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The released Prdx2 then acts to induce
production of inflammatory cytokines,
like a classical inflammatory danger sig-
nal (11). Studies by others also have
shown that Prdx1, 5 and 6 also induce in-
flammatory cytokines in vitro (12,13).
However, Prdxs (except Prdx4) do not
have signal peptides and, therefore, must
be secreted by alternative, nonclassical
mechanisms as postulated for IL-1β (14)
and HMGB1 (15). Here we test the hy-
pothesis that cysteine oxidation is a pre-
requisite for the release of Prdx1 and 2.
For this purpose we set up an experi-
mental model where Prdx release is in-
duced from HEK 293T cells upon stimu-
lation with TNF-α. Previous studies have
shown that HEK 293T cells respond to
TNF-α (but not LPS) by secreting IL-8
(16); hence this system was used as a
model of a proinflammatory stimulus.
We then expressed different cysteine mu-
tants of Prdx1 and 2 to investigate the
role of specific cysteines in the secretion
of these proteins, both in response to LPS
and an oxidant, menadione. Release of a
classical cytokine, IL-8, was used for
comparison. We also investigated
whether Prdx1 and 2 were released in ex-
osomes and whether an inhibitor of the
classical secretory pathway, brefeldin A
(BFA), affected their secretion. The re-
sults presented here confirm that the
presence and oxidation of specific cys-
teines in Prdx1 and 2 are an essential re-
quirement for their secretion through the
exosomal pathway.
MATERIALS AND METHODS
Reagents
LPS from E. coli 055:B5, glyburide,
nocodazole, brefeldin A (BFA), mena-
dione and N-ethylmaleimide (NEM)
were all purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Cloning and Mutation of Human Prdx2
and Human Prdx1 in pcDNA6
Human Prdx1 and 2 were initially
cloned from human cDNA into the
pGEM-T plasmid (Promega, Southamp-
ton, UK) using specific oligonucleotides
(Table 1). Inserts were restricted using
specific endonucleases and were ligated
into the expression plasmid pet15b 
(Novagen; Millipore, Watford, Hertford-
shire, UK). All cysteines (hPrdx1: C52S,
C71S, C83S and C172S; hPrdx2: C51S,
C70S and C172S) were changed to serine
residues by rolling circle PCR using spe-
cific oligonucleotides as shown in Table 1.
Sequences were then amplified using the
following oligonucleotides: Prdx2 sense:
5′–CAG AAG CTT ATG GCC TCC GGT
AAC GCG CGC ATC–3′ and anti-sense:
5′-CAG CTC GAG AT ATT GTG TTT
GGA GAA ATA TTC CTT–3′; Prdx1
sense 5′–CTA AAGCTT ATG TCT TCA
GGA AAT GCT AAA ATT–3′ and anti-
sense 5′–CTAG CTCGAG CG CTT CTG
CTT GGA GAA ATA TTC TTT–3′ for
cloning into the mammalian expression
plasmid pcDNA6 (Life Technologies
[Thermo Fisher Scientific Inc., Waltham,
MA, USA]). For expression of GFP-Prdx2
fusion proteins, sequences coding for
W/T or C51S Prdx2 were cloned down-
stream of the eGFP sequence in pcDNA3
using HindIII and EcoRI restriction sites.
The sequence of all constructs was veri-
fied by sequencing.
Cloning and Mutation of Rat HMGB-1
in pcDNA6
Rat HMGB-1 was amplified from rat
cDNA (a generous gift from Huan Yang,
The Feinstein Institute for Medical Re-
search, Manhasset, NY, USA) by PCR
using Pfu-DNA polymerase (Promega)
using primers designed to insert restriction
sites for HindIII and XhoI. Inserts were re-
stricted using HindIII and XhoI and ligated
into pcDNA6 (Life Technologies [Thermo
Fisher Scientific]). All cysteines (C23S,
C45S and C106S) were first changed to ser-
ine residues using the QuikChange Light-
ning site-directed mutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA) and
the oligonucleotides shown in Table 1.
Double and triple cysteine mutations were
achieved by additional rounds of site-
 directed mutagenesis. The mutations of all
constructs were verified by sequencing.
Culture and Transient Transfection of
293T Cells
293T cells were routinely cultured in-
Dulbecco modified Eagle medium
(DMEM) (Sigma-Aldrich) supplemented
with 10% fetal bovine serum and penicil-
lin and streptomycin. Transient transfec-
Table 1. Oligonucleotides used in the cloning and mutagenesis of human Prdx1, human Prdx2 and rat HMGB-1.
Protein Mutagenesis Primer forward Primer reverse
Prdx1 WT — CATATGTCTTCAGGAAATGCTAAAATTGG GGATCCTCACTTCTGCTTGGAGAAATATTC
Prdx1 C52S CACCTTTGTGTCCCCCACG CGTGGGGGACACAAAGGTG
Prdx1 C71S GAAACTCAACTCCCAAGTGATTG CAATCACTTGGGAGTTGAGTTTC
Prdx1 C83S GATTCTCACTTCTCTCATCTAGCATG CATGCTAGATGAGAGAAGTGAGAATC
Prdx1 C173S GAAGTGTCCCCAGCTG CAGCTGGGGACACTTC
Prdx2 WT — CATATGGCCTCCGGTAACGCG GGATCCCTAATTGTGTTTGGAGAAATATTCCTTG
Prdx2 C51S CACTTTTGTGTCCCCCACCGAGATC GATCTCGGTGGGGGACACAAAAGTG
Prdx2 C70S CAAAGCTGGGCAGTGAAGTGCTG CAGCACTTCACTGCCCAGCTTTG
Prdx2 C172S CATGGGGAAGTTAGTCCCGCTGCTG CAGCCAGCGGGACTAACTTCCCCATG
HMGB-1 W/T — CTAAAGCTTATGGGCAAAGGAGATCCTAAGAAG CTAGCTCGAGCGTTCATCATCATCATCTTCTTCTTC
HMGB-1 C23S TCATATGCATTTTTTGTGCAAACTTCTCGGGAGGAGCAT ATGCTCCTCCCGAGAAGTTTGCACAAAAAATGCATATGA
HMGB-1 C45S TCAGAGTTTTCTAAGAAGAGCTCAGAGAGGTGGAAG CTTCCACCTCTCTGAGCTCTTCTTAGAAAACTCTGA
HMGB-1 C106S GCCTTCTTCCTCTTCAGCTCTGAGTATCGCC GGCGATACTCAGAGCTGAAGAGGAAGAAGGC
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tions were performed using 25-kDa linear
polyethylenimine (PEI) (purchased from
Polysciences Inc., Warrington, PA, USA).
Stock solutions of PEI were prepared in
water at a concentration of 1 mg/mL, and
the pH adjusted to 7.0. The transfection
conditions used are essentially those as
described previously (17). Briefly, HEK
293T cells were plated at a density of 0.5 ×
106 cells/well in 6-well plates and trans-
fected with 5 μg of DNA. The transfection
complex was formed at a DNA-PEI ratio
of 1:3 in OPTI-MEM (Life Technologies
[Thermo Fisher Scientific]), with a 30 min
incubation at room temperature prior to
addition to the cells. Twenty-four hours
later, culture media were replaced with
1 mL of serum-free DMEM containing
50 ng/mL of recombinant human TNF-α
(PeproTech, Rocky Hill, NJ, USA). Cells
were cultured for a further 24 h before col-
lecting supernatants and lysing cells in 
200 μL of lysis buffer (10 mmol/L Tris
HCl, 150 mmol/L NaCl, 1 mmol/L ethyl-
ene glycol tetraacetic acid (EGTA),
1 mmol/L ethylenediaminetetraacetic acid
(EDTA), 1% NP-40, pH 7.4). NEM was
added to all supernatants and cell lysates
to a final concentration of 50 mmol/L im-
mediately after collection and incubated at
room temperature for 15 min. In some ex-
periments, cell viability was determined at
the end of the experiment using the
CellTiter-Blue assay (Promega) according
to the manufacturer’s instructions.
Culture of THP-1 Cells
THP-1 monocytic cells were routinely
cultured in RPMI (Sigma-Aldrich) sup-
plemented with 10% fetal bovine serum
and penicillin and streptomycin. For
stimulation of THP-1 cells with LPS, cells
were treated with 100 ng/mL of LPS in
serum-free RPMI and cultured for 24 h
before collecting cells and supernatants
by centrifugation. NEM was again added
to all supernatants and cell lysates to a
final concentration of 50 mmol/L imme-
diately after collection.
Western Blotting
293T cell culture supernatants or
cleared cell lysates were applied with-
out prior dilution to 12% acrylamide
sodium dodecyl sulphate (SDS) gels
and transferred to nitrocellulose mem-
branes (Millipore) by electroblotting.
After blocking in 5% bovine serum al-
bumin (BSA) in PBS containing 0.05%
Tween 20, membranes were probed
with one of the following antibodies:
polyclonal rabbit anti-human Prdx2 or
Prdx1 antibody, mouse anti-His (Life
Technologies [Thermo Fisher Scien-
tific]), mouse anti-V5 (Life Technologies
[Thermo Fisher Scientific]), mouse anti-
Prdx4 (Santa Cruz Biotechnology Inc.,
Dallas, TX, USA), mouse anti-Prdx5
(Santa Cruz Biotechnology), rabbit 
anti-HSP70 (Sigma-Aldrich), mouse
anti-actin (Sigma-Aldrich) followed by
detection with anti-rabbit-IgG-horse-
radish peroxidase conjugate (Sigma-
Aldrich) or anti-mouse IgG horseradish
peroxidase conjugate (Stratagene, Agi-
lent Technologies). In some experi-
ments, membranes were stripped using
Restore stripping buffer (Pierce Scien-
tific [Thermo Fisher Scientific]) before
blocking and reprobing with an anti-
body as described above. Western blots
were developed using advanced chemi-
luminescence (ECL) reagents (GE
Healthcare, Amersham, UK) and ex-
posed to autoradiography using Hyper-
film (GE Healthcare). Films were devel-
oped using an AGFA Curix 60 developer
(Agfa HealthCare, Brentford, Middle-
sex, UK).
Cell Viability Assays
Cell viability was measured using the
CellTiter-Glo assay (Promega) according
to the manufacturer’s instructions. To
confirm that this assay was sensitive
enough to determine even relatively small
levels of cellular toxicity, varying numbers
of 293T cells were plated, incubated at
37°C for 24 h to allow cells to adhere, then
cell viability measured.
IL-8 ELISA
The concentration of IL-8 secreted by
HEK 293T cells was determined using
as commercially available enzyme-
linked immunosorbent assay (ELISA)
kit (R&D Systems, Minneapolis, MN,
USA).
Purification of Recombinant hPrdx2
from HEK293T Cells
HEK 293T cells transiently transfected
with pcDNA6-hPrdx2 were lysed in ice-
cold lysis buffer (50 mmol/L sodium
phosphate pH 8.0, 300 mmol/L NaCl,
0.01% Tween20, Triton 100), centrifuged
to remove cell debris and applied to a
His Gravi-Trap Talon column (GE
Healthcare). Columns were washed ex-
tensively with washing buffer (50 mmol/L
sodium phosphate pH 8.0, 300 mmol/L
NaCl, 0.01% Tween20, 50 mmol/L imida-
zole) and eluted with elution buffer 
(50 mmol/L sodium phosphate pH 8.0,
300 mmol/L NaCl, 0.01% Tween20, 
300 mmol/L imidazole). The eluted
Prdx2 was buffer exchanged into PBS
(pH 7.4) using a PD10 desalting column
(GE Healthcare).
Preparation of Exosomes
Serum-free medium (1 ml) from cul-
tured cells was collected, treated with
NEM to a final concentration of 
50 mmol/L and incubated at room tem-
perature for 15 min, then centrifuged at
2,000g for 10 min to remove cells and 
cell debris. Supernatants were then 
centrifuged at 100,000g at 4°C for 2 h,
washed with PBS, and centrifuged again
for 1 h and the resulting supernatants
collected. Pellets (exosomes) were resus-
pended in SDS-PAGE sample buffer 
(50 mmol/L Tris-Cl [pH 6.8], 100 mmol/L
dithiothreitol, 2% SDS, 0.1% bromophe-
nol blue, 10% glycerol) and subjected to
12% SDS-PAGE under nonreducing con-
ditions for Western blot analysis as de-
scribed above.
Collection of Human Plasma
Human peripheral blood was collected
from healthy donors, all of whom gave
written informed consent, under the ap-
proval of the local Research Governance
and Ethics Committee. Blood was col-
lected in vacutainers containing EDTA.
Immediately after collection, blood was
centrifuged at 1,000g to pellet cells. The
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plasma was removed and NEM added to
a final concentration of 50 mmol/L. For
preparation of exosomes from plasma,
samples were centrifuged at 10,000g for
30 min at 4°C. The supernatants were
then centrifuged at 100,000g at 4°C for 2
h, and the resulting pellets washed with
PBS, before centrifuging at 100,000g at
4°C for 1 h. Pellets were lysed in SDS
sample buffer for subsequent analysis by
Western blotting.
All supplementary materials are available
online at www.molmed.org.
RESULTS
TNF-α- and Oxidant-Induced Release
of Prdx2 Homodimer
Our previous work showed that Prdx1
and 2 were released from cultured cells
(RAW 267 and cultured human PBMCs)
in response to inflammatory stimuli and,
intriguingly, all of the released Prdx was
in the dimeric form (10). To investigate
the mechanisms of this release, we used a
HEK 293 cell model system, with TNF-α
as the proinflammatory stimulus. We
first investigated the time course of re-
lease of Prdx2 from HEK 293 cells in re-
sponse to stimulation with TNF-α (Fig-
ure 1A). The release of Prdx2 was
maximal 24 h after stimulation with
TNF-α. Intracellular Prdx2 was present
both as monomer and dimer, while the
released protein was all in the dimeric
form (Figure 1B). Reduction with dithio-
threitol (DTT) confirmed the presence of
disulfide-linked homodimers. It is im-
portant to note that the concentration of
TNF-α used was not significantly toxic,
as assessed by CellTiter-Glo cell viability
assay (Figure 2A), an assay which can
detect even a 5% decrease in cell viability
(Figure 2B). Furthermore, there was no
actin detected in the supernatants of
these cells by Western blotting (Figure 2C).
We could also show that Prdx2 is re-
leased in response to the oxidant mena-
dione and the vast majority of Prdx2 was
present in the supernatant as a dimer
(Figure 1C). The monomer was only ob-
served in minute amounts, except with
the highest concentrations of menadione,
which resulted in 83% and 28% toxicity
respectively (see Figure 2A), and sub-
stantial amounts of monomer released.
Thus, the Prdx2 homodimer can be re-
leased not only upon cell death but also
Figure 1. Endogenous (E) and recombinant (R) Prdx2 are released from HEK 293T cells in re-
sponse to treatment with TNF-α. (A) Time course of Prdx2 release in response to treatment
with TNF-α analyzed by Western blotting following nonreducing SDS-PAGE of conditioned
media from 293T cells expressing recombinant Prdx2 using anti-Prdx2 antibody. The two arrows
indicate rPrdx2 (upper band), which is larger due to V5, and His tags and endogenous Prdx2
(lower band). (B) Intracellular and extracellular levels of endogenous (E) and recombinant (R)
Prdx2 in HEK 293T cells ± TNF-α treatment for 24 h (left, gel run under nonreducing conditions;
right, reducing). The dimeric form disappears under reducing conditions. (C) Release of en-
dogenous and recombinant Prdx2 from HEK 293T cells 24 h after menadione treatment.
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by a specific process of secretion induced
by oxidants or TNF-α. Interestingly,
while both menadione and TNF-α in-
duced release of Prdx2, only TNF-α, but
not menadione, induced release of IL-8
(IL-8 pg/mL: control, 4 ± 0.1; menadione,
0.1 ± 0.1; TNF-α, 2500 ± 140; n = 6).
TNF-α Induces Release of Prdx1 and 2
but Not Prdx4 or 5
Release of Prdx1 from HEK 293 cells
upon stimulation with TNF-α is identical
to that of Prdx2. As shown in Figure 3A,
only the dimer of Prdx1 was released in
response to TNF-α. By contrast, neither
Prdx4 nor Prdx5 were released at detect-
able levels. Of note, while intracellular
Prdx1, like Prdx2, also was present as a
disulfide-linked dimer, Prdx4 and 5 were
not. In fact, Prdx4 was detected (Figure 3B)
as a 31-kDa membrane form and a
27-kDa processed form, consistent with
previous reports (18). Despite the fact
that Prdx4 has a signal peptide and re-
portedly can be secreted, none of it was
detectable in the supernatant of HEK 293
cells upon TNF-α stimulation. Prdx5 was
detected as a single 17-kDa monomer
and did not form a dimer (Figure 3C),
consistent with the knowledge that
Prdx5, an atypical Prdx, forms an in-
tramolecular disulfide rather than a
dimer, during its catalytic cycle (19). Fur-
thermore, no Prdx4 or 5 were detectable
in the supernatants from LPS-stimulated
RAW cells (data not shown), in contrast
to Prdx1 and 2, indicating that these dif-
ferences are not peculiar to HEK 293 cells
or to the human system.
Stability of the Monomer in Cell
Culture Conditions
The observation that only dimeric
Prdx1 and 2 were ever detected in the
supernatants of cultured cells raised the
question of whether this reflected the fact
that only dimers were released or
whether a mixture of monomers and
dimer were released with subsequent ox-
idation of monomer to dimer. To distin-
guish between these two possibilities, we
purified recombinant Prdx2 from HEK
293T cells. The resulting preparation con-
sisted of a mixture of monomers and
dimers (Figure 4A). The purified Prdx2
was incubated with HEK 293T cultures
at 37°C for 24 h and analyzed by Western
blotting. Both monomer and dimer were
still present in the cell-conditioned me-
dium, with an even higher ratio of
monomer to dimer than the input mate-
rial (Figure 4B).
Disulfide-Mediated Dimerization Is
Essential for Release of Prdx1 and 2
The data shown above led us to hy-
pothesize that cysteine oxidation, by
formation of a disulfide-linked dimer, is
a prerequisite for the release of Prdx1
and 2. We thus overexpressed single-
cysteine mutants of Prdx1 and Prdx2 in
HEK 293 cells and studied their secre-
tion in response to TNF-α. As shown in
Figure 5D, intracellular wild-type re-
combinant Prdx1 (detected with an anti-
V5 tag antibody) is present as both
monomer and dimer. Mutating either
Cys52 or Cys173 prevented dimeriza-
tion of Prdx1, while mutations of Cys71
or Cys83 had no effect. Prdx1 was se-
creted in response to TNF-α solely in
the dimeric form, and blocking dimer-
ization by mutating Cys52 or Cys173
prevented secretion (Figure 5F). We per-
formed a similar set of experiments for
Prdx2, this time with three cysteine mu-
tations, as Prdx2 has one cysteine fewer
than Prdx1. The Western blot for intra-
cellular recombinant Prdx2 (E) and se-
creted Prdx2 (G) is shown in Figure 5.
Intracellular recombinant wild-type
Prdx2 (detected using an anti-His tag
antibody) was present both as monomer
and dimer. Mutation of Cys51 or Cys172
prevented the formation of the dimer,
while mutation of Cys70 had no effect
on dimerization. Secretion of the recom-
binant protein also was stimulated by
TNF-α, in a manner similar to the en-
Figure 2. Cell toxicity does not account for the Prdx2 observed in HEK 293T cell culture super-
natants. (A) Cell viability measured by CellTiter-Glo assay 24 h after treatment with 50 ng/mL
TNF-α or varying concentrations of menadione. ** p < 0.0001; *p < 0.02, versus control by
Dunnett test with one-way analysis of variance (ANOVA). (B) Sensitivity of the CellTiter-Glo
assay demonstrated by plating varying numbers of 293T cells. *p < 0.005 versus control. 
(C) Western blot analysis of actin in the supernatants or (D) cell lysates from 293T cells.
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dogenous protein, although it should be
noted that this is likely also due to the
increased expression of the recombinant
proteins (Figure 5G, arrow). Mutation of
either Cys51 or Cys172 inhibited the re-
lease of the proteins, while mutation of
noncatalytic cysteines did not inhibit se-
cretion. In fact, mutation of Cys71 or
Cys83 in Prdx1 (see Figure 5F) or Cys70
in Prdx2 (Figure 5G) slightly increased
their release.
An appreciable amount of monomer
was observed in the cell supernatants for
the first time, but only when disulfide
bond formation was prevented by muta-
tion of Cys51 or Cys172. One possibility
was that overexpression of these mutant
proteins was causing protein aggregation
and consequent cellular toxicity. To de-
termine whether this was the case and
whether cellular location was affected by
the mutation, we expressed wild-type
and C51S Prdx2 as GFP- fusion proteins
for analysis by confocal microscopy.
wild-type GFP-Prdx2 was visible as
punctate cytoplasmic staining, in con-
trast to the GFP control, which showed
diffuse staining throughout the cyto-
plasm and nucleus (Supplementary Fig-
ures 1A, B). The C51S mutant GFP-fusion
was present in much larger aggregates
within the cytoplasm (Supplementary
Figure 1C). Staining of endogenous
Prdx2 by immunofluorescent labeling
confirmed that the punctate cytoplasmic
staining observed for the wild-type re-
combinant Prdx2 accurately reflected the
localization of the endogenous protein
(Supplementary Figure 1D).
An important question was whether
this phenomenon of cysteine oxidation
Figure 3. Release of other Prdx proteins from HEK 293T cells. (A) Release of endogenous
(E) and recombinant (R) Prdx1 in response to treatment with TNF-α analyzed by Western
blotting following nonreducing SDS-PAGE. Intracellular expression of Prdx1 consists of
both monomers and dimers and DTT treatment results in the disappearance of the
dimeric form. (B) and (C). Absence of Prdx4 (B) and Prdx5 (C) in the conditioned media
of HEK 293T cells ± TNF-α. Both proteins (indicated by arrows) were detected in cell
lysates by Western blotting following nonreducing SDS-PAGE with anti-Prdx4 and anti-
Prdx5 respectively.
Figure 4. Purified recombinant Prdx2 does
not form dimers in HEK 293T cell culture.
(A) Recombinant Prdx2 consists of
monomer and dimer, which can be re-
duced to monomer by treatment with DTT.
Removal of DTT results in reversion to a
mixture of monomers and dimers. (B) Incu-
bation of recombinant Prdx2 (shown by
arrow in panel A) with HEK 293T cell for 
24 h does not result in oxidation of
monomer to dimer.
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and resultant dimerization as a require-
ment for release from stimulated cells
applied to the release of other proteins in
response to inflammatory stimuli. The
obvious candidate to investigate was the
well-characterized inflammatory danger
signal, HMGB1. This protein previously
has been shown to switch between redox
states in response to inflammation (20)
and, importantly, the nucleocytoplasmic
localization is impaired by mutation of
one of the three cysteine residues. We
generated four forms of recombinant
HMGB1, wild-type, C23S, C106S and
triple cysteine-to-serine mutations to in-
vestigate whether cysteine mutation
could impair secretion in the manner ob-
served for Prdx1 and 2. Recombinant
HMGB-1 was released from HEK 293
cells in response to TNF-α but none of
the cysteine mutations affected the re-
Figure 5. Mutation of cysteines involved in disulfide bond formation prevents release of
Prdx1 and Prdx2 from HEK 293T cells. (A) Catalytic mechanism of Prdx2. The peroxidatic
cysteine C51 (C52 in Prdx1) reacts with peroxide then with the resolving cysteine C172
(C173 in Prdx1) on the second subunit of the dimer to form disulfide bonds. (B) Prdx1 and
(C) Prdx2 cysteine mutants. Intracellular expression of recombinant wild-type and mu-
tated Prdx1 (D) and Prdx2 (E) in HEK 293T cell lysates analyzed by Western blotting with
anti-V5 or anti-His antibody, respectively, following nonreducing SDS-PAGE to allow identifi-
cation of monomers and dimers. Release of Prdx1 (F) and Prdx2 (G) also were analyzed
by Western blotting of conditioned media from HEK 293T cells ± TNF-α using specific anti-
bodies following nonreducing SDS-PAGE.
Figure 6. Mutation of cysteine residues
does not prevent release of HMGB-1
from HEK 293T cells. (A) Intracellular ex-
pression of recombinant wild-type and
mutated HMGB-1 in HEK 293T cell lysates
analyzed by Western blotting with anti-
V5 antibody following reducing SDS-
PAGE. Cell lysates were diluted 50-fold
before applying to gel. (B) Release of
HMGB-1 from HEK 293T cells analyzed by
Western blotting of conditioned media
applied to gel without dilution using anti-
V5 antibody following reducing SDS-
PAGE. (C) Densitometric analysis of re-
leased HMGB-1 expressed as a
percentage of intracellular HMGB-1.
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lease of HMGB1 from HEK 293 cells in
response to TNF-α (Figure 6).
Prdx1 and 2 Dimers Are Secreted via
a Nonclassical Pathway and Are
Associated with the Exosomes
The lack of signal peptides in Prdx1
and 2 suggests a nonclassical pathway
for secretion. We wondered, however,
whether the dimer could be secreted
through the Golgi. Therefore, we tested
the effect of a known inhibitor of classi-
cal secretion, BFA, on the secretion of
Prdx2 from TNF-α-stimulated HEK 293
cells. As shown in Supplementary Fig-
ure 2A, BFA did not inhibit TNF-α-in-
duced Prdx2 secretion. In fact, BFA
alone induced some release of Prdx2,
possibly due to nonspecific toxicity. To
confirm the inhibitory effect of BFA on
the classical secretary pathway, we mea-
sured the concentration of a classically
secreted cytokine, IL-8. As shown in
Supplementary Figure 2B, BFA com-
pletely blocked release of IL-8. We also
tested the effects of glyburide and noco-
dazole, known inhibitors of the release
of a nonclassically secreted cytokine,
IL-1β. As shown in Supplementary Fig-
ures 2C and D, glyburide and nocoda-
zole actually increased the amount of
Prdx2 dimer released. Because several
inflammatory proteins can be secreted
though the exosomal pathway (21,22),
we investigated whether the Prdx1 and 2
released from HEK 293 cells were asso-
ciated with exosomes. For this purpose,
we isolated exosomes from the super-
natants of control or TNF-α-stimulated
HEK 293 cells using ultracentrifugation.
Figure 7 shows the levels of Prdx1 and 2
present in the exosomes and in the su-
pernatant left after removal of exosomes
(Figures 7A, B). It can be seen that there
is a strong association of Prdx1 and 2
with the exosomal fraction. To assess
the validity of the fractionation method
used here, we also measured an exoso-
mal marker, HSP70 (23), and the results
shown in Figures 7A and B confirm its
enrichment in the exosomal fraction.
Identical results were obtained using a
second method of exosome isolation,
further confirming the association of
Prdx2 with the exosomes (Supplemen-
tary Figure 3). Similar results were ob-
tained in THP-1 cells (a human mono-
cytic cell line) when stimulated with
LPS. Dimeric Prdx1 and 2 were released
from THP-1 cells in response to LPS,
and are also associated with the exoso-
mal fraction as shown in Figures 7C 
and D.
Prdx2 Is Present as Dimers in Human
Plasma
To determine whether this mecha-
nism also occurs in vivo, we analyzed
Prdx2 in human plasma. Prdx2 was de-
tected in human plasma by Western
blotting using specific antibodies as
shown in Figures 7E and F. The major-
ity of Prdx2 was present as oligomers,
Figure 7. Both Prdx1 and Prdx2 are associated with exosomes in cell culture supernatants
and in healthy human serum. Western blot analysis of (A,C) Prdx1 or (B,D) Prdx2 present in
exosomal or cytosolic fractions of supernatants from (A,B) HEK 293T cells or from (C,D)
THP-1 cells. Blots were stripped and reprobed with anti-HSP70 antibody to confirm the
presence of exosomes. (E) Western blotting of human serum from four healthy donors
using anti-Prdx2 following nonreducing SDS-PAGE. Addition of DTT reduces the dimers to
monomers. (F) Exosomes were prepared from serum samples by ultracentrifugation and
analyzed by Western blotting with anti-Prdx2 in nonreducing and reducing conditions.
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with some dimer present. Upon treat-
ment of the samples with DTT, the
oligomeric form disappeared and most
of the protein was reduced to
monomers (Figure 7E).We could also
show that, similar to the conditioned
medium from cultured cells, the Prdx2
present in plasma was associated with
exosomes (see Figure 7F).
DISCUSSION
Here we show a novel redox-regu-
lated mechanism for the extracellular re-
lease of Prdx1 and 2 in response to in-
flammatory stimuli. The lack of a signal
peptide in these proteins meant that
classical secretion was unlikely and this
was confirmed by the fact that release of
these proteins was unaffected by BFA.
The aim of the study was to test the hy-
pothesis that cysteine oxidation is impli-
cated in the release of Prdx1 and 2. The
observation that only the dimer is pres-
ent in the supernatant raised the possi-
bility that secreted Prdx, whether in
monomeric or dimeric form, would be
oxidized after its release in our culture
conditions. However, when recombinant
Prdx2 originally present both as
monomer and dimer was added to 
cultured cells, we could still detect 
both monomer and dimer. Thus, if a
mixture of monomer and dimer was 
secreted, this would be detected in the
supernatant.
Prdx1 and 2 are typical 2-Cys Prdxs,
which rely on two specific cysteine
residues for their catalytic activity, with
a peroxidatic cysteine that is oxidized to
a sulfenic acid by H2O2 and a resolving
one which then reduces it by forming a
disulfide bridge (Figure 5A). The perox-
idatic cysteines are Cys52 or 51, while
the resolving ones are Cys173 or 172, in
Prdx1 and 2 respectively. Prdx2 has one
(Cys70) and Prdx1 has two (Cys71 and
Cys83) additional cysteines. Consistent
with the mechanism shown in Figure
5A, we found that mutation of the per-
oxidatic or resolving cysteines pre-
vented dimerization, while mutation of
the additional cysteine had no effect on
dimerization. Intriguingly, mutation of
either the peroxidatic or the resolving
cysteines in both Prdx1 and 2 prevented
secretion from cells
The one exception to this was the
C51S mutation of Prdx2, which was ob-
served in the supernatant in the
monomeric form. It is possible, how-
ever, that the appearance of the Prdx2
monomer in the supernatants of cells
expressing the C51S mutant is an arti-
fact of recombinant expression and ag-
gregation of this protein. This is sup-
ported by experiments showing that,
when expressed as a GFP-fusion pro-
tein, the C51S mutant is present in large
aggregates in the cytoplasm, while the
wild-type protein is present as uni-
formly distributed punctate staining in
the cytoplasm. Secretion of misfolded
or overexpressed proteins is a phenom-
enon previously described for various
proteins and is thought to represent a
means by which the cytoplasm can be
cleared of aggregated or accumulated
protein (24,25). As there does not ap-
pear to be any difference in the extent
of expression for the wild-type and
C51S mutant, it seems more likely that
the release of the monomer in the case
of the C51S mutant is due to the lack of
dimerization which seems to cause ag-
gregation within the cells. Of note, the
corresponding C52S mutant in Prdx1
did not behave in this manner, with the
overall evidence suggesting that muta-
tions which prevented dimerization
also prevented secretion. It is clear from
the preceding discussion that, although
mutation of individual cysteines is the
only way of determining their impor-
tance, there are some limitations to this
approach. However, with the exception
of the experiments with the C51S mu-
tant, the evidence points to a role for
cysteine oxidation in the secretion of
Prdx1 and 2.
There is a growing list of proteins
that are secreted by nonclassical path-
ways (26), and our finding might define
a class of them whose secretion is medi-
ated by the redox state of the protein.
Interestingly, dimerization via the for-
mation of covalent dimers is also essen-
tial for the secretion of fibroblast
growth factor (FGF) 1 (27), as point mu-
tation of Cys30 inhibits export of this
protein (28). FGF1 is also one of a group
of nonclassically secreted proteins that
are not released spontaneously, but that
require cell stress to be secreted (26).
However, the similarities between re-
lease of FGF1 and Prdx 1 and 2 end
there. In fact, although FGF1 homod-
imers are absolutely necessary for se-
cretion, they form only one part of a
much larger multiprotein complex that
is required for release (29,30). Export
from the cell then occurs via transloca-
tion through the cell membrane (31)
and not via exosomal release, as shown
here for Prdx1 and 2.
The release of the dimer in response to
proinflammatory stimulation or oxidant
treatment must reflect a change in intra-
cellular trafficking of the dimer to asso-
ciate with exosomes. It is interesting to
note that oxidation and subsequent
dimerization of Prdx2 does seem to pro-
mote membrane-association of the pro-
tein as shown in human erythrocytes
(32) and rat myocardium (33). As both
monomer and dimer are present in un-
stimulated cells, but with little or no re-
lease in the absence of stimulation (10)
(this study), it may be the ratio of
monomer to dimer that determines the
association of the dimer with the exo-
somes and subsequent export from the
cell as postulated in Figure 8.
It is difficult to say whether glu-
tathionylation is important for this pro-
cess. Our previous work has shown that
both Prdx1 and 2 are released from
mouse macrophage cells in response to
LPS as glutathionylated dimers (10). One
possibility is that the glutathionylation
releases monomers and dimers from
larger multimeric structures that, as
such, would normally be retained in the
cell. In fact, Prdx1 dimers can organize
in decamers (34) and it was shown that,
while normally 97% of the protein is in
this form, glutathionylation completely
eliminates these decamers, releasing
monomers and dimers (35). Although
the decameric form was not investigated
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specifically in this study, it is likely that
the dimers that are secreted are released
from these higher-order oligomers.
The mechanism of release of Prdx1 and
2 is distinct from that for Il-1β, which can
be inhibited by glyburide or nocodazole.
It is unsurprising that glyburide does not
inhibit the release of Prdxs, as this com-
pound inhibits activation of the NLRP3
inflammasome, hence inhibiting the pro-
cessing of pro-IL1 to mature IL-1β for se-
cretion, while Prdx1 and 2 do not un-
dergo proteolytic processing during
secretion. However, secretion of IL-1β
also can be inhibited by cytoskeletal in-
hibitors such as nocodazole (36), demon-
strating the involvement of microtubules
in the exocytosis of the vesicles contain-
ing IL-1β (36). It appears from the results
shown here that microtubules are unim-
portant for the release of Prdx1 and 2 and
the major determining factor in their re-
lease is dimerization via cysteine oxida-
tion. The fact that the oxidant menadione
also induces the release of Prdx1 and 2
suggest that oxidation per se is sufficient
to cause their release.
The redox regulation of these Prdxs is
of particular importance as the proin-
flammatory activity of both Prdx1
(11,12) and Prdx2 (10,13) has been
demonstrated previously. The fact that
these Prdxs are released in a redox-reg-
ulated manner in response to inflamma-
tory stimuli as well as oxidant treatment
is the first evidence for the potential
generation of inflammatory mediators
by cellular redox changes. The redox en-
zyme TXN also is released from RAW
cells in response to LPS in an oxidized
(glutathionylated) form (10) and also is
released during infection and inflamma-
tion and has immunoregulatory effects
(37). Similarly to the Prdxs shown here,
secretion of TXN occurs by a nonclassi-
cal pathway (38), but intriguingly, secre-
tion is independent of redox state (39).
Other proinflammatory molecules se-
creted in exosomes or vesicles include
HSP70 (21) and HMGB-1 (40). HSP70 is
released from cells in exosomes (23), but
there is no evidence that its association
with exosomes is associated with
changes in its redox status. Although
redox changes are important in control-
ling the intracellular localization of
HMGB-1 in terms of nuclear versus cy-
toplasmic localization (41), extracellular
secretion of HMGB-1 is independent of
redox state.
CONCLUSION
We have uncovered a novel mecha-
nism for nonclassical secretion of in-
flammatory mediators that relies on
cysteine oxidation and might poten-
tially define a “redox secretome.” The
presence of Prdx1 and 2 in healthy
human plasma suggests that redox
changes, by controlling their secretion,
regulate their role in inflammation.
This may be particularly important in
pathologies such as ischemia-reperfu-
sion injury, where an inflammatory re-
sponse is observed in the absence of in-
fection or autoimmunity, and where a
redox imbalance may act as the trigger
of inflammation. A comprehensive 
definition of the redox secretome in
pathological conditions might open
new perspectives in terms of pharma-
cological targets or biomarkers for sev-
eral diseases.
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